• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.

作者信息

Blennow Ola, Salmanton-García Jon, Nowak Piotr, Itri Federico, Van Doesum Jaap, López-García Alberto, Farina Francesca, Jaksic Ozren, Pinczés László Imre, Bilgin Yavuz M, Falces-Romero Iker, Jiménez Moraima, Ormazabal-Vélez Irati, Weinbergerová Barbora, Duléry Rémy, Stojanoski Zlate, Lahmer Tobias, Fernández Noemí, Hernández-Rivas José-Ángel, Petzer Verena, De Jonge Nick, Glenthøj Andreas, De Ramón Cristina, Biernat Monika M, Fracchiolla Nicola, Aujayeb Avinash, Van Praet Jens, Schönlein Martin, Méndez Gustavo-Adolfo, Cattaneo Chiara, Guidetti Anna, Sciumè Mariarita, Ammatuna Emanuele, Cordoba Raul, García-Poutón Nicole, Gräfe Stefanie, Cabirta Alba, Wolf Dominik, Nordlander Anna, García-Sanz Ramón, Delia Mario, Berg Venemyr Caroline, Brones Clara, Di Blasi Roberta, De Kort Elizabeth, Meers Stef, Lamure Sylvain, Serrano Laura, Merelli Maria, Coppola Nicola, Bergantim Rui, Besson Caroline, Kohn Milena, Petiti Jessica, Garcia-Vidal Carolina, Dargenio Michelina, Danion François, Machado Marina, Bailén-Almorox Rebeca, Hoenigl Martin, Dragonetti Giulia, Chai Louis Yi Ann, Kho Chi Shan, Bonanni Matteo, Liévin Raphaël, Marchesi Francesco, Cornely Oliver A, Pagano Livio

机构信息

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany.

出版信息

Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.

DOI:10.1002/ajh.26626
PMID:35702878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9349555/
Abstract
摘要

相似文献

1
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.血液系统恶性肿瘤患者感染奥密克戎SARS-CoV-2变异株的结局：一项EPICOVIDEHA调查报告
Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.
2
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.接受替沙格韦单抗/西加韦单抗被动预先暴露免疫的血液系统恶性肿瘤合并 COVID-19 患者：EPICOVIDEHA 登记研究的配对分析。
J Hematol Oncol. 2023 Apr 1;16(1):32. doi: 10.1186/s13045-023-01423-7.
3
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.COVID-19合并血液系统恶性肿瘤重症患者的重症监护需求及预后：EPICOVIDEHA调查结果
Infection. 2024 Jun;52(3):1125-1141. doi: 10.1007/s15010-023-02169-7. Epub 2024 Feb 22.
4
Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies.在血液系统恶性肿瘤患者中，感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变异株的结果与感染先前变异株相似。
Ann Hematol. 2022 Aug;101(8):1877-1878. doi: 10.1007/s00277-022-04833-8. Epub 2022 Apr 7.
5
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.接种疫苗的血液系统恶性肿瘤成年患者中的 COVID-19：来自 EPICOVIDEHA 的初步结果。
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
6
Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.与实体瘤或血液系统恶性肿瘤患者 SARS-CoV-2 感染和结局相关的因素：一项单中心研究。
Support Care Cancer. 2021 Nov;29(11):6271-6278. doi: 10.1007/s00520-021-06175-z. Epub 2021 Apr 14.
7
Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience.严重急性呼吸综合征冠状病毒 2 奥密克戎变异株在费城染色体阴性骨髓增殖性肿瘤患者中的表现：一项单中心经验。
Oncology. 2022;100(8):460-466. doi: 10.1159/000525750. Epub 2022 Jul 26.
8
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.土耳其血液系统恶性肿瘤患者 COVID-19 的临床特征和结局。
Turk J Haematol. 2022 Feb 23;39(1):43-54. doi: 10.4274/tjh.galenos.2021.2021.0287. Epub 2021 Sep 15.
9
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
10
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.接种 BNT162b2 mRNA 疫苗的血液恶性肿瘤移植患者体内 SARS-CoV-2 抗体和固有细胞因子减少。
Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022.

引用本文的文献

1
Antiviral Combination Treatment for COVID-19 in Immunocompromised Patients: Towards Defining Its Place in Therapy.免疫功能低下患者COVID-19的抗病毒联合治疗：明确其在治疗中的地位
Infect Dis Ther. 2025 Sep 15. doi: 10.1007/s40121-025-01231-1.
2
Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.奥密克戎时代血液学患者和细胞治疗接受者感染新型冠状病毒期间的合并感染：西班牙造血干细胞移植和细胞治疗组研究
BMC Infect Dis. 2025 Jul 25;25(1):944. doi: 10.1186/s12879-025-11302-w.
3
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对B细胞淋巴增殖性疾病患者双特异性抗体治疗的影响。
Blood Adv. 2025 Aug 26;9(16):4180-4189. doi: 10.1182/bloodadvances.2024015406.
4
Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.早期干预以及单克隆抗体与抗病毒药物联合治疗对感染SARS-CoV-2的肿瘤血液学患者的有效性：一项回顾性研究经验
Front Immunol. 2025 Mar 28;16:1524525. doi: 10.3389/fimmu.2025.1524525. eCollection 2025.
5
Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.尼马曲韦/利托那韦成功治疗1例接受R-CHOP方案治疗滤泡性淋巴瘤后发生多次复发新型冠状病毒肺炎的患者
Cureus. 2025 Feb 14;17(2):e79019. doi: 10.7759/cureus.79019. eCollection 2025 Feb.
6
Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.继发感染对血液系统恶性肿瘤合并SARS-CoV-2感染患者预后的影响：HM-COV 3.0研究结果
Viruses. 2025 Feb 16;17(2):274. doi: 10.3390/v17020274.
7
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
8
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.2023 - 2024年寒温带秋冬季节血液系统恶性肿瘤患者中的呼吸道病毒：EPICOVIDEHA - EPIFLUEHA报告
Am J Hematol. 2025 Mar;100(3):358-374. doi: 10.1002/ajh.27565. Epub 2024 Dec 23.
9
[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].慢性淋巴细胞白血病患者新冠病毒病的单中心研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):923-930. doi: 10.3760/cma.j.cn121090-20240621-00230.
10
Risk factors for COVID-19 pneumonia in patients with hematological malignancies: a multi-center, prospective study in China.中国多中心前瞻性研究：血液病患者 COVID-19 肺炎的危险因素。
Front Immunol. 2024 Nov 7;15:1408969. doi: 10.3389/fimmu.2024.1408969. eCollection 2024.

本文引用的文献

1
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.在奥密克戎时代，CLL 患者因 COVID-19 而死亡的风险较低。
Blood. 2022 Aug 4;140(5):445-450. doi: 10.1182/blood.2022016147.
2
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者对 SARS-CoV-2 奥密克戎亚谱系 BA.1 和 BA.2 的血清中和作用。
Nat Med. 2022 Jun;28(6):1297-1302. doi: 10.1038/s41591-022-01792-5. Epub 2022 Mar 23.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎（B.1.1.529）和德尔塔（B.1.617.2）变异株的关系：一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性：前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
5
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.mRNA-1273 对 SARS-CoV-2 奥密克戎和德尔塔变异株的有效性。
Nat Med. 2022 May;28(5):1063-1071. doi: 10.1038/s41591-022-01753-y. Epub 2022 Feb 21.
6
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
7
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.德克萨斯州休斯顿的 2019 年冠状病毒病患者中，由严重急性呼吸综合征冠状病毒 2 的奥密克戎变异株引起的疫苗突破性增加、住院率降低和疾病严重程度降低的信号。
Am J Pathol. 2022 Apr;192(4):642-652. doi: 10.1016/j.ajpath.2022.01.007. Epub 2022 Feb 3.
8
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
9
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.血液系统恶性疾病成人患者对新冠疫苗接种的抗体反应
JAMA Oncol. 2021 Nov 1;7(11):1714-1716. doi: 10.1001/jamaoncol.2021.4381.
10
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19.EPICOVIDEHA：一个用于COVID-19血液病患者流行病学研究的即用型平台。
Hemasphere. 2021 Jun 25;5(7):e612. doi: 10.1097/HS9.0000000000000612. eCollection 2021 Jul.